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Abstract
Background: Esophageal carcinoma is the ninth most prevalent cancer worldwide with squamous
cell carcinoma (SCCA) and adenocarcinoma accounting for the vast majority of new cases (13,900
in 2003). Cure rates in the U.S. are less than 10%, similar to lung cancer. More than 50% of patients
with esophageal carcinoma present with unresectable or metastatic disease, are not surgical
candidates, or display disease progression despite the addition of neoadjuvant chemoradiotherapy
to surgery. Need for improved palliation exits.
Case presentation: This case describes a 73-year-old African American male who presented
with recurrent squamous cell carcinoma (SCCA) of the esophagus who has a achieved complete
remission for 24 months via endoscopic cryospray ablation.
Conclusion:  Endoscopic cryo spray ablation warrants further investigation as a palliative
treatment modality for esophageal cancer. This is the first reported case in the medical literature.
Background
Esophageal carcinoma is the ninth most prevalent cancer
worldwide with squamous cell carcinoma (SCCA) and
adenocarcinoma accounting for the vast majority of new
cases (13,900 in 2003 in the USA) [1,2]. Cure rates in the
U.S. are less than 10%, similar to lung cancer [3]. The
definitive surgical therapy, esophagectomy, can provide
10–26%, 5-year, disease-free, all-stage survival rates [3,4].
However, more than 50% of patients with esophageal car-
cinoma present with unresectable or metastatic disease
and are not surgical candidates, or display disease progres-
sion despite the addition of neoadjuvant chemoradiother-
apy to surgery [3-5].
Cryospray ablation (CSA) using liquid nitrogen sprayed
through a low pressure device has recently been described
to be effective and safe in the treatment of Barrett's
esophagus including high-grade dysplasia [6-12]. This
case report describes the first use of CSA in a patient with
recurrent SCCA for palliative treatment that has resulted
in complete remission for 2 years.
Case presentation
A 73 year old African American male with history of SCCA
of the esophagus presented with mild dysphagia. Subse-
quent endoscopy (EGD) revealed recurrent SCCA of the
esophagus. Seven years prior he was diagnosed with a T1-
2, N1 SCCA of the left anterior tonsillar pillar and treated
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with radiation therapy (XRT) (6660 cyG to the primary
tumor). Four years later he developed Stage III esophageal
SCCA (T4, N0, M0), by chest CT, located at 33 cm from
the incisors that was 3 cm in length. This lesion was
treated with 5400 cGy XRT and chemotherapy with cura-
tive intent. On the third (current) presentation, a moder-
ately differentiated, T2, by endoscopic ultrasound (EUS),
SCCA lesion at 24 cm was discovered (Figure 1 and 2).
This new lesion was above the prior field of XRT and prox-
imal to the original stage III esophageal SCCA.
The patient was evaluated by the institution's tumor
board and deemed neither a surgical nor XRT candidate
based on significant cardiac comorbidities and maximum
dose XRT with his prior treatments. Palliative treatment
options were explored. Based on the success with ablation
of esophageal lesions as described above, palliation via
CSA was pursued for this patient. At the time of this case,
the device was under an investigational device exemption
(IDE) issued by the FDA. Therefore, an FDA Humanitar-
ian Use Device exemption was requested and granted for
use of the CSA device. The patient signed a consent form
approved by the authors IRB and the FDA. The patient's 2
cm long, hemi-circumferential SCCA was treated with two
30 second pulses of CSA under direct endoscopic visuali-
zation on an outpatient basis (Figure 3). This particular
dosimetry was chosen based on early clinical trials in Bar-
rett's esophagus and swine data. The first CSA of Barrett's
esophagus in clinical trials used a dose of 40 seconds (two
20 second applications separated by a 20–30 second
thaw). Early animal studies at the author's institution
(unpublished) have demonstrated that the depth of injury
correlates with duration of freeze. High grade dysplasia
has been effectively treated with CSA at 20 seconds times
three cycles. Thus in hope of achieving greater depth of
injury without excessive necrosis, two cycles of 30 seconds
each were applied. CSA was applied in such a way that the
entire tumor with margins of 1–2 cm was frozen. This
technique resulted in a near circumferential freeze of the
esophagus but with a focus on the tumor which endo-
scopically appeared hemi-circumferential in distribution.
Interestingly, freezing of the tumor under direct endo-
scopic visualization demonstrated that the tumor differ-
entially retracted when frozen relative to the surrounding
esophageal mucosa making the margins of the tumor
more distinct. Prior to freezing, the margins of the tumor
diffusely blended into the esophageal wall.
This patient was treated with lansoprazole 30 mg BID
throughout the CSA period. The patient experienced no
initial complications. One month latter a follow-up EGD
revealed endoscopic resolution of the tumor, but biopsies
remained positive for moderately differentiated SCCA
(Figure 4). CSA of the area was repeated, treating 40% of
the esophageal circumference 4 cm in length spanning the
prior SCCA with three, 20 second pulses. This shorter
pulsed duration of CSA was chosen because less depth of
injury was desired based on the significant response with
the initial treatment. Increased numbers of CSA cycles are
associated with greater tissue injury. Therefore the intent
Histology of figure 1 Figure 2
Histology of figure 1. This is a moderately differentiated 
SCCA (H&E).
Squamous cell carcinoma (SCCA) in the proximal esophagus  at 24 cm from the incisors Figure 1
Squamous cell carcinoma (SCCA) in the proximal esophagus 
at 24 cm from the incisors. This lesion occurred above the 
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was a more intense treatment but with less depth of
injury. Twenty-four hours later, the patient experienced
odynophagia requiring oral narcotics for 3 weeks fol-
lowed by the development of a stricture at one month
post-CSA. This was treated with Savary dilation but has
subsequently become a persistent esophageal stricture at
that the site. Biopsies at the cancer site 6 weeks after the
second cryoablation and bimonthly in the subsequent 12
months of follow-up were completely negative for dyspla-
sia or neoplasia.
The persistent esophageal stricture (Figure 5) has required
multiple dilations with various types of dilators (with and
without corticosteroid injections) and temporary (3
month) esophageal stent (Polyflex®  by Wilson Cook)
placement. The patient continues to work and remains
cancer free 24 months post-treatment.
Discussion
Despite ongoing research in esophageal cancer, the overall
median survival following curative esophagectomy has
been shown to be 34–38.6 months [13,14] with a 7
month median survival following detection of recurrent
esophageal cancer [14]. Palliation therapies are needed
for both survival prolongation and symptom relief. Cur-
rent palliation approaches include feeding tubes, dilation,
stents, radiation, chemotherapy and various ablative tech-
niques, all of which have benefits and risks [4,15].
Fibrotic stricture which developed after the second cry- ospray ablation treatment Figure 5
Fibrotic stricture which developed after the second cry-
ospray ablation treatment.
Cryospray ablation (CSA) of the SCCA in figure 1 Figure 3
Cryospray ablation (CSA) of the SCCA in figure 1. On the 
left is the cryo decompression tube. In the right fore corner 
is the cryo catheter.
Endoscopic appearance of the SCCA (figure 1) one month  after cryospray ablation Figure 4
Endoscopic appearance of the SCCA (figure 1) one month 
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The mechanism of action underlying the injury caused by
CSA is unique for an ablative technique. CSA induces
apoptosis and causes cryonecrosis at super-cold tempera-
tures (-76°C to -158°C), which results in transient
ischemia at the CSA site and can cause immune stimula-
tion [16]. Some precancerous lesions such as Barrett's epi-
thelium and many cancers are resistant to apoptosis and
therefore might be uniquely suited for treatment by CSA
[17]. Work in the swine has laid the foundations for the
use of CSA. Initially, research was conducted to define the
optimum cryogen dosimetry. This was followed by depth-
of-injury work using endoscopic ultrasonography (EUS)
and then comparative trials of CSA, MPEC and APC.
Depth of injury at doses of 20 seconds times two cycles
approximates 2 mm. Longer duration freezes achieve
greater depths of injury [11].
It is unclear at this point what stages of esophageal cancer
could potentially be treated/palliated with this modality.
However, in this particular case and based on the degree
of stricturing that followed it is likely that full esophageal
wall thickness injury occurred. Thus palliation of tumors
up to T4 (tumor invading adjacent structures) is conceiv-
able.
The stricture that developed in this case was significant
and required multiple interventions. Other potential
complications of CSA include perforation, and bleeding.
It is unknown what the actual complication rates are for
this modality at this dose due to its relative novelty. In the
first trial published by Johnston et al., no complications
were reported. They used a dosimetry of 20 seconds times
two for the first 10 patients. The CSA complication rate
relative to other ablation techniques such as photody-
namic therapy (PDT) is also unknown. However, for PDT
the esophageal stricture rate is 30 to 50% depending on
the number of treatments.
This particular malignancy may have been a very indolent
one with slow growth as evidenced by the significant time
interval between the first and second esophageal cancer
presentation. It is also conceivable that only one CSA
treatment was necessary for the palliation of this tumor in
that "cure" is highly unlikely in such a case. One applica-
tion of CSA may have avoided the subsequent stricture.
However, this case still represents the first of its kind in the
medical literature using this device and technique to
achieve a sustained remission for SCCA of the esophagus.
CSA has advantages relative to other palliative measures
in that it is simple to use, can be performed with a stand-
ard diagnostic upper endoscope, is relatively inexpensive,
and has a low rate of complications [12]. There is no pho-
tosensitivity as in PDT and most patients after CSA can
resume eating and a normal lifestyle the same day.
Although treatment of this patient resulted in a post treat-
ment stricture, he has no evidence of recurrent malig-
nancy two years post treatment. A sustained remission of
this nature in recurrent SCCA is unusual. Although specu-
lative, this sustained remission could relate to the unique
mechanisms of action of CSA. These mechanisms of
injury include the induction of apoptosis, cryonecrosis,
and systemic anti-tumor immune stimulation [18-20].
The effectiveness of CSA in the treatment of neoplasms
such as prostate cancer can also be enhanced by certain
chemotherapeutic agents such as 5-fluorouracil [20].
These mechanisms of injury in concert with the method of
delivery may make CSA an ideal option for the palliative
treatment of esophageal neoplasms. Pilot studies indicate
that mucosa damaged by cryotherapy followed by healing
in an acid-free environment results in re-epithelialization
with normal squamous epithelium in the majority of
patients [12].
Conclusion
Some precancerous lesions such as Barrett's epithelium
and many cancers are resistant to apoptosis and therefore
might be uniquely suited for treatment by CSA. This case
report describes the first use of CSA in a patient with recur-
rent SCCA for palliative treatment that has resulted in
complete remission for 2 years. Further investigation
using CSA as a palliative measure for esophageal cancer
should be considered.
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